Experts are looking forward to the upcoming clinical trials of the cancer drug, nilotinib. A 2015 study reveals that nilotinib has a dramatic impact with regards to improving the conditions of patients with Parkinson’s disease and Alzheimer’s disease.
A new study has discovered that an FDA-approved leukemia drug, nilotinib, is able to improve the cognition, motor and non-motor functions in patients suffering from Parkinson's and Alzheimer's diseases.
